at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
Company profile
Ticker
KURA
Exchange
Website
CEO
Troy Wilson
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ZETA ACQUISITION CORP III
SEC CIK
KURA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
UPLOAD
Letter from SEC
29 Feb 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
424B3
Prospectus supplement
15 Feb 24
EFFECT
Notice of effectiveness
15 Feb 24
CORRESP
Correspondence with SEC
14 Feb 24
Transcripts
KURA
Earnings call transcript
2023 Q3
2 Nov 23
KURA
Earnings call transcript
2023 Q2
3 Aug 23
KURA
Earnings call transcript
2023 Q1
10 May 23
KURA
Earnings call transcript
2022 Q4
23 Feb 23
KURA
Earnings call transcript
2022 Q3
3 Nov 22
KURA
Earnings call transcript
2022 Q2
3 Aug 22
KURA
Earnings call transcript
2022 Q1
5 May 22
KURA
Earnings call transcript
2021 Q4
25 Feb 22
KURA
Earnings call transcript
2021 Q3
7 Nov 21
KURA
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Flynn James E
12 Feb 24
4
THOMAS JAMES DOYLE
31 Jan 24
4
KATHLEEN FORD
31 Jan 24
4
Teresa Brophy Bair
31 Jan 24
4
STEPHEN DALE
31 Jan 24
144
Notice of proposed sale of securities
30 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 28.74 mm | 28.74 mm | 28.74 mm | 28.74 mm | 28.74 mm | 28.74 mm |
Cash burn (monthly) | 6.86 mm | 5.18 mm | 14.16 mm | 12.85 mm | 9.68 mm | 9.75 mm |
Cash used (since last report) | 46.80 mm | 35.34 mm | 96.52 mm | 87.60 mm | 65.96 mm | 66.50 mm |
Cash remaining | -18.06 mm | -6.60 mm | -67.78 mm | -58.86 mm | -37.22 mm | -37.76 mm |
Runway (months of cash) | -2.6 | -1.3 | -4.8 | -4.6 | -3.8 | -3.9 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 134 |
Opened positions | 9 |
Closed positions | 26 |
Increased positions | 65 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 684.98 bn |
Total shares | 83.48 mm |
Total puts | 91.50 k |
Total calls | 10.30 k |
Total put/call ratio | 8.9 |
Largest owners | Shares | Value |
---|---|---|
Suvretta Capital Management | 7.34 mm | $66.90 bn |
BLK Blackrock | 6.92 mm | $63.12 bn |
BVF | 6.73 mm | $61.39 bn |
EcoR1 Capital | 5.81 mm | $52.96 bn |
Deerfield Management | 4.37 mm | $39.89 bn |
Flynn James E | 4.37 mm | $42.43 mm |
Vanguard | 3.92 mm | $35.79 bn |
Biotechnology Value Fund L P | 3.80 mm | $0.00 |
STT State Street | 3.26 mm | $29.70 bn |
Avoro Capital Advisors | 2.98 mm | $27.18 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Jan 24 | Stephen Dale | Common Stock | Sell | Dispose S | No | Yes | 21.5502 | 4,825 | 103.98 k | 38,817 |
29 Jan 24 | Thomas James Doyle | Common Stock | Sell | Dispose S | No | No | 17.8005 | 963 | 17.14 k | 48,093 |
29 Jan 24 | Thomas James Doyle | Common Stock | Sell | Dispose S | No | No | 17.8005 | 761 | 13.55 k | 49,056 |
29 Jan 24 | Thomas James Doyle | Common Stock | Sell | Dispose S | No | No | 17.8005 | 594 | 10.57 k | 49,817 |
29 Jan 24 | Kathleen Ford | Common Stock | Sell | Dispose S | No | No | 17.8005 | 1,496 | 26.63 k | 21,602 |
29 Jan 24 | Teresa Brophy Bair | Common Stock | Sell | Dispose S | No | No | 17.8005 | 2,053 | 36.54 k | 68,979 |
29 Jan 24 | Stephen Dale | Common Stock | Sell | Dispose S | No | No | 17.8005 | 2,758 | 49.09 k | 43,642 |
29 Jan 24 | Stephen Dale | Common Stock | Sell | Dispose S | No | No | 17.8005 | 4,400 | 78.32 k | 46,400 |
24 Jan 24 | Troy Edward Wilson | Common Stock | Sell | Dispose S | No | Yes | 20.23 | 84,107 | 1.70 mm | 559 |
24 Jan 24 | Troy Edward Wilson | Common Stock | Option exercise | Acquire M | No | Yes | 6.15 | 84,107 | 517.26 k | 84,666 |
News
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
22 Apr 24
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
6 Mar 24
HC Wainwright & Co. Reiterates Buy on Kura Oncology, Maintains $32 Price Target
28 Feb 24
Wedbush Reiterates Outperform on Kura Oncology, Maintains $37 Price Target
28 Feb 24
Kura Oncology: Q4 Earnings Insights
27 Feb 24
Press releases
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
22 Apr 24
Kura Oncology to Participate in Stifel Targeted Oncology Forum
10 Apr 24
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Apr 24
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
6 Mar 24
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Mar 24